Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

FT825 · ONO-8250

Cell therapy (CAR-T) · Kills target cells, directed at HER2 (ERBB2) (ERBB2) · developed by Fate Therapeutics

Phase 1 Most advanced trial
FATE Developer
1 Registered trials

What is FT825?

FT825 is an off-the-shelf allogeneic CAR T-cell preparation derived from induced pluripotent stem cells, with a chimeric antigen receptor directed against HER2 (ERBB2). It targets and induces toxicity in HER2-expressing tumor cells and is being studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ONO-8250
Drug type
Cell therapy (CAR-T)
Targets
HER2 (ERBB2) (ERBB2) (antigen)
Mechanism
Kills target cells, directed at HER2 (ERBB2) (ERBB2)
Pathways
antibody-dependent cellular cytotoxicity, TGF-beta signaling redirection, IL-7 signaling
Therapy area
Oncology
Developer
Fate Therapeutics (FATE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06241456 Phase 1 Advanced Solid Tumor Recruiting FATE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

Other drugs acting on ERBB2

More from Fate Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.

Follow FATE, the company behind FT825

See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FATE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.